HIV CTL escape: At what cost?

被引：18

作者：

Smith S.M. ^{[1
]}

机构：

[1] Saint Michael's Medical Center, The New Jersey Medical School, Newark

来源：

Retrovirology | / 1卷 / 1期

关键词：

Viral Load; Simian Immunodeficiency Virus; Escape Mutation; Major Histocompatibility Complex Allele; Viral Fitness;

D O I：

10.1186/1742-4690-1-8

中图分类号：

学科分类号：

摘要：

Recent data have established the HIV-1 and SIV escape CTL through epitope mutation. However, three novel studies prove that such escape comes at a "cost" to overall viral fitness. Understanding how HIV-1/SIV escape CTL and the impact of the escape mutations has tremendous importance in developing CTL based vaccines. Further, a CTL based HIV-1 vaccine is likely to have long-term protective effect against disease only if the escape virus is significantly weakened compared with wild type. © 2004 Smith; licensee BioMed Central Ltd.

引用

页数：5

共 14 条

[1]

Hanke T., Development of prophylactic AIDS vaccines: The current state of affairs, Curr. Opin. Mol. Ther., 5, pp. 25-32, (2003)

[2]

Barouch D.H., Letvin N.L., Viral evolution and challenges in the development of HIV vaccines, Vaccine, 20, SUPPL. 4, (2002)

[3]

Klenerman P., Wu Y., Phillips R., HIV: Current opinion in escapology, Curr. Opin. Microbiol., 5, pp. 408-413, (2002)

[4]

Friedrich T.C., Dodds E.J., Yant L.J., Vojnov L., Rudersdorf R., Cullen C., Evans D.T., Desrosiers R.C., Mothe B.R., Sidney J., Sette A., Kunstman K., Wolinsky S., Piatak M., Lifson J., Hughes A.L., Wilson N., O'Connor D.H., Watkins D.I., Reversion of CTL escape-variant immunodeficiency viruses in vivo, Nat. Med., 10, pp. 275-281, (2004)

[5]

Leslie A.J., Pfafferott K.J., Chetty P., Draenert R., Addo M.M., Feeney M., Tang Y., Holmes E.C., Allen T., Prado J.G., Altfeld M., Brander C., Dixon C., Ramduth D., Jeena P., Thomas S.A., John A.S., Roach T.A., Kupfer B., Luzzi G., Edwards A., Taylor G., Lyall H., Tudor-Williams G., Novelli V., Martinez-Picado J., Kiepiela P., Walker B.D., Goulder P.J., HIV evolution: CTL escape mutation and reversion after transmission, Nat. Med., 10, pp. 282-289, (2004)

[6]

O'Connor D.H., Mothe B.R., Weinfurter J.T., Fuenger S., Rehrauer W.M., Jing P., Rudersdorf R.R., Liebl M.E., Krebs K., Vasquez J., Dodds E., Loffredo J., Martin S., McDermott A.B., Allen T.M., Wang C., Doxiadis G.G., Montefiori D.C., Hughes A., Burton D.R., Allison D.B., Wolinsky S.M., Bontrop R., Picker L.J., Watkins D.I., Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cyto

[7]

Goulder P.J., Bunce M., Krausa P., McIntyre K., Crowley S., Morgan B., Edwards A., Giangrande P., Phillips R.E., McMichael A.J., Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection, AIDS Res. Hum. Retroviruses, 12, pp. 1691-1698, (1996)

[8]

Kaslow R.A., Carrington M., Apple R., Park L., Munoz A., Saah A.J., Goedert J.J., Winkler C., O'Brien S.J., Rinaldo C., Detels R., Blattner W., Phair J., Erlich H., Mann D.L., Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection, Nat. Med., 2, pp. 405-411, (1996)

[9]

Migueles S.A., Sabbaghian M.S., Shupert W.L., Bettinotti M.P., Marincola F.M., Martino L., Hallahan C.W., Selig S.M., Schwartz D., Sullivan J., Connors M., HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors, Proc. Natl. Acad. Sci. U. S. A., 97, pp. 2709-2714, (2000)

[10]

Tang J., Tang S., Lobashevsky E., Myracle A.D., Fideli U., Aldrovandi G., Allen S., Musonda R., Kaslow R.A., Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1, J. Virol., 76, pp. 8276-8284, (2002)

← 1 2 →